AU2010313255B2 - The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders - Google Patents

The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders Download PDF

Info

Publication number
AU2010313255B2
AU2010313255B2 AU2010313255A AU2010313255A AU2010313255B2 AU 2010313255 B2 AU2010313255 B2 AU 2010313255B2 AU 2010313255 A AU2010313255 A AU 2010313255A AU 2010313255 A AU2010313255 A AU 2010313255A AU 2010313255 B2 AU2010313255 B2 AU 2010313255B2
Authority
AU
Australia
Prior art keywords
dinaline
subject
day
administered
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010313255A
Other languages
English (en)
Other versions
AU2010313255A1 (en
Inventor
Johannes Graeff
Ji-Song Guan
Stephen J. Haggarty
Edward Holson
Li-Huei Tsai
Florence Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Massachusetts Institute of Technology
Broad Institute Inc
Original Assignee
General Hospital Corp
Massachusetts Institute of Technology
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Massachusetts Institute of Technology, Broad Institute Inc filed Critical General Hospital Corp
Publication of AU2010313255A1 publication Critical patent/AU2010313255A1/en
Application granted granted Critical
Publication of AU2010313255B2 publication Critical patent/AU2010313255B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010313255A 2009-10-30 2010-10-29 The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders Ceased AU2010313255B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25692709P 2009-10-30 2009-10-30
US61/256,927 2009-10-30
US26546809P 2009-12-01 2009-12-01
US61/265,468 2009-12-01
PCT/US2010/054872 WO2011053876A1 (en) 2009-10-30 2010-10-29 The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders

Publications (2)

Publication Number Publication Date
AU2010313255A1 AU2010313255A1 (en) 2012-05-31
AU2010313255B2 true AU2010313255B2 (en) 2015-04-30

Family

ID=43922604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010313255A Ceased AU2010313255B2 (en) 2009-10-30 2010-10-29 The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders

Country Status (9)

Country Link
US (2) US8563615B2 (OSRAM)
EP (1) EP2493298A4 (OSRAM)
JP (1) JP2013509441A (OSRAM)
CN (1) CN102834002A (OSRAM)
AU (1) AU2010313255B2 (OSRAM)
CA (1) CA2779497A1 (OSRAM)
IN (1) IN2012DN03807A (OSRAM)
NZ (1) NZ599757A (OSRAM)
WO (1) WO2011053876A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011795A2 (en) * 2007-07-13 2009-01-22 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
US8263547B2 (en) * 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
NZ599757A (en) 2009-10-30 2014-08-29 Massachusetts Inst Technology The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
JP6240063B2 (ja) * 2011-04-28 2017-11-29 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
ES2719266T3 (es) 2011-07-22 2019-07-09 Massachusetts Inst Technology Activadores de histona desacetilasas de clase I (HDACS), y usos de los mismos
CA2880117C (en) 2012-07-27 2021-04-06 The Broad Institute, Inc. Inhibitors of histone deacetylase
US20150219673A1 (en) * 2012-09-04 2015-08-06 Massachusetts Institute Of Technology The use of gene expression profiling as a biomarker for assessing the efficacy of hdac inhibitor treatment in neurodegenerative conditions
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
EP3737362B1 (en) 2018-01-12 2025-10-15 Kdac Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
GB202001023D0 (en) * 2020-01-24 2020-03-11 Univ Leicester HDAC Degrader
CN112062826A (zh) * 2020-06-01 2020-12-11 暨南大学 一种与中枢神经衰老相关的乙酰化修饰h2b蛋白标记分子及其应用
WO2023034440A1 (en) * 2021-09-01 2023-03-09 Case Western Reserve University Treatment of neurodegenerative diseases with hdac inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
US20070129331A1 (en) * 2004-04-20 2007-06-07 Rnd Pharmaceuticals, Inc. Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives
US20070197438A1 (en) * 2005-11-08 2007-08-23 The General Hospital Corporation Dynamin mediated diseases and associated methods and products

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US6110697A (en) 1995-09-20 2000-08-29 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
DE60034688T2 (de) 1999-09-08 2008-01-17 Sloan-Kettering Institute For Cancer Research Kristallstruktur einer deacetylase und deren inhibitoren
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
JP2001149081A (ja) 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
WO2002030879A2 (en) * 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US20060148743A1 (en) 2001-05-18 2006-07-06 Vasant Jadhav RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
AU2002318364A1 (en) 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
JP4638148B2 (ja) * 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20050227300A1 (en) 2001-12-07 2005-10-13 Atadja Peter W Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
CA2473505A1 (en) 2002-02-07 2003-08-14 Ellen M. Leahy Novel bicyclic hydroxamates as inhibitors of histone deacetylase
WO2003066885A2 (en) 2002-02-08 2003-08-14 Novartis Ag Method for screening for compounds having hdac inhibitory activity
US20050288227A1 (en) 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
US20030224473A1 (en) 2002-05-23 2003-12-04 Mccafferty Dewey G. Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors
KR20050074487A (ko) 2002-10-17 2005-07-18 메틸진, 인크. 히스톤 데아세틸라아제의 억제제
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
WO2005030705A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
US20050227929A1 (en) * 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
EP1591109B1 (en) * 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
US20060008517A1 (en) * 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
US20060018921A1 (en) * 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
WO2006052916A2 (en) 2004-11-08 2006-05-18 Errant Gene Therapeutics, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20070015183A1 (en) 2005-06-03 2007-01-18 The General Hospital Corporation Biomarkers for huntington's disease
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
AU2006287378A1 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by HDac inhibition
AU2006312084A1 (en) 2005-11-03 2007-05-18 Merck Sharp & Dohme Corp. Substituted nicotinamide compounds
AU2007221207A1 (en) 2006-02-28 2007-09-07 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
JP5554988B2 (ja) 2006-04-07 2014-07-23 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
CA2649861A1 (en) 2006-04-26 2007-11-08 Merck & Co., Inc. Disubstituted aniline compounds
US8119652B2 (en) 2006-05-18 2012-02-21 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
WO2008008472A2 (en) 2006-07-13 2008-01-17 President And Fellows Of Harvard College Methods and compositions for modulating synapse formation
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
WO2009011795A2 (en) * 2007-07-13 2009-01-22 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
US8263547B2 (en) * 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
CA2734991A1 (en) * 2008-07-23 2010-01-28 Massachusetts Institute Of Technology Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
NZ593447A (en) * 2008-12-03 2012-12-21 Harvard College Inhibition of hdac2 to promote memory
US9265764B2 (en) * 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
NZ599757A (en) * 2009-10-30 2014-08-29 Massachusetts Inst Technology The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
ES2719266T3 (es) * 2011-07-22 2019-07-09 Massachusetts Inst Technology Activadores de histona desacetilasas de clase I (HDACS), y usos de los mismos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US20070129331A1 (en) * 2004-04-20 2007-06-07 Rnd Pharmaceuticals, Inc. Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
US20070197438A1 (en) * 2005-11-08 2007-08-23 The General Hospital Corporation Dynamin mediated diseases and associated methods and products

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Langley, B. et al. Current Drug Targets - CNS & Neurological Disorders (2005) Vol.4 No.1 pages 41 to 50 *
LATTAL, K.M. et al. "Systemic or Intrahippocampal Delivery of Histone Deacetylase Inhibitors Facilitates Fear Extinction" Behavioral Neuroscience (2007) Vol.121 No.5 pges 1125 to 1131 *
Sleiman, S.F. et al. Expert Opinion on Investigational Drugs (2009) Vol.18 No.5 pages 573 to 584 *

Also Published As

Publication number Publication date
CA2779497A1 (en) 2011-05-05
AU2010313255A1 (en) 2012-05-31
JP2013509441A (ja) 2013-03-14
IN2012DN03807A (OSRAM) 2015-08-28
US20110224303A1 (en) 2011-09-15
EP2493298A1 (en) 2012-09-05
US20120322879A1 (en) 2012-12-20
EP2493298A4 (en) 2013-04-10
US8563615B2 (en) 2013-10-22
NZ599757A (en) 2014-08-29
WO2011053876A1 (en) 2011-05-05
US8841346B2 (en) 2014-09-23
CN102834002A (zh) 2012-12-19

Similar Documents

Publication Publication Date Title
AU2010313255B2 (en) The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US8088951B2 (en) Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US11377423B2 (en) Inhibitors of histone deacetylase
US7705017B2 (en) Compounds for treatment of neurodegenerative diseases
JP6093180B2 (ja) ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
JP2012510512A (ja) 記憶を推進するためのｈｄａｃ２の阻害
AU2017201599A1 (en) APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF
JP2024097004A (ja) 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
CA2692775A1 (en) Methods of enhancing cognitive function using non-peptidic compounds
US20210038589A1 (en) Uses, compositions and methods
Diniz et al. Histone deacetylase inhibition mitigates cognitive deficits and astrocyte dysfunction induced by amyloid‐β (Aβ) oligomers
JP2011518188A (ja) リソソーム調節のための化合物および使用方法
CN112979546B (zh) 一类丁酰胆碱酯酶选择性抑制剂及其制备方法与用途
CN119546323A (zh) 用于治疗与bbb渗透性相关的障碍或疾病的爱帕琳肽受体调节剂
CN114521142A (zh) 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
CN116981449A (zh) 用于引起神经保护的化合物和组合物
WO2017071799A1 (en) Lpa level reduction for treating central nervous system disorders
US20240207282A1 (en) Method of increasing chaperone mediated autophagy by stabilizing the interaction of retinoic acid receptor-alpha and an inhibitor
US20190085029A1 (en) Cyclin-dependent kinase 5 (cdk5) inhibitory peptides
US20190201376A1 (en) Method for Treating or Preventing Fatty Acid Binding Protein 3 Induced B-amyloid Aggregation Diseases
Guix Ràfols Study of the pathophysiological role of nitric oxide on the amyloid-induced toxicity attending to the biochemical modifications and cellular damages
WO2007065080A2 (en) Control of apoptosis by controlling the propensity of ceramide channel formation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired